Nkarta Targets ACR 2026 Data Reveal as Outpatient CAR NK Trials Advance

Nkarta expects to present initial clinical data from its autoimmune disease programs at the American College of Rheumatology's November 2026 Convergence meeting. Planned disclosures will cover myositis, scleroderma, and program-wide safety, creating a future clinical catalyst but providing no efficacy or financial results yet.